Articles related to Oncology, Radiation

Dedifferentiated liposarcoma, a malignancy with significant metastatic potential, requires precise diagnosis through MRI, PET scans, and genetic testing. MDM2 and CDK4 are pivotal markers for distinguishing DDL from other sarcomas.

Women experiencing persistent bloating, abnormal bleeding, or chronic fatigue should seek medical evaluation as these symptoms may signal various types of cancer.

Many modern oncology trials prioritize drug approval over patient welfare, often using inferior control arms that do not reflect the best available treatment.

The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.

With nearly ten years of follow-up, dabrafenib plus trametinib demonstrates a sustained improvement in survival outcomes for patients with stage III BRAF V600–mutated melanoma, presenting a viable long-term strategy in melanoma management.